Evidence map›Paper›PMID 26408180›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.

Chun-Lin Zhang, Kun-Peng Zhu, Guo-Qi Shen, Zhong-Sheng Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Decoding LncRNAs.Cancers · 2021
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Chun-Lin ZhangDepartment of Orthopaedic Surgery, Shanghai Tenth People's Hospital Affiliated to Tongji University, 301, Yan-chang Middle Road, Shanghai, 200072, People's Republic of China. shzhangchunlin123@163.com.
Kun-Peng ZhuDepartment of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233, People's Republic of China.
Guo-Qi ShenDepartment of Orthopaedic Surgery, Shanghai Sixth People's Hospital, Soochow University, Shanghai, 200233, People's Republic of China.
Zhong-Sheng ZhuDepartment of Orthopaedic Surgery, Shanghai Tenth People's Hospital Affiliated to Tongji University, 301, Yan-chang Middle Road, Shanghai, 200072, People's Republic of China.
Shanghai Sixth People's Hospital · CNShanghai Tenth People's Hospital · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are emerging in molecular biology as crucial regulators of cancer. Although the aberrant expression of lncRNAs has been observed in osteosarcoma (OS), the molecular mechanisms underlying lncRNAs in doxorubicin resistance of OS still unknown. In the current study, we investigated a novel lncRNA, termed ODRUL (osteosarcoma doxorubicin-resistance related up-regulated lncRNA), and evaluated its role in the occurrence of doxorubicin resistance in OS. LncRNA microarray revealed that lncRNA ODRUL was the most up-regulated expressed in the doxorubicin-resistant OS cell line. Quantitative real-time PCR (qRT-PCR) confirmed that lncRNA ODRUL was higher in different doxorubicin-resistant OS cell lines and lower in different doxorubicin-sensitive OS cell lines. Moreover, we showed that lncRNA ODRUL was increased in specimens of OS patients with a poor chemoresponse and lung metastasis. We further demonstrated that lncRNA ODRUL inhibition could inhibit OS cell proliferation, migration, and partly reversed doxorubicin resistance in vitro. In addition, we found that the expression of classical drug resistance-related ATP-binding cassette, subfamily B, member 1 (ABCB1) gene was decreased after the lncRNA ODRUL knockdown. Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells .These findings may provide a novel target for reversing doxorubicin resistance in OS.

Indexed as

AdolescentAdultApoptosisATP Binding Cassette Transporter, Subfamily BBone NeoplasmsCell Line, TumorCell MovementCell ProliferationChildDoxorubicinDrug Resistance, NeoplasmFemaleHumansLung NeoplasmsMaleOsteosarcomaABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BDoxorubicinRNA, Long NoncodingDoxorubicin resistanceLncRNAODRULOsteosarcoma

Identifiers

PMID26408180
OpenAlexW2130703448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.